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Cisplatin-induced and ATM-phosphorylated (p)-DNp63a regulates the expression of epidermal dif-
ferentiation and skin barrier regulators (AQP3, CASP14, ALOX12B, and CLDN1) in squamous cell car-
cinoma (SCC) cells by dual transcriptional and post-transcriptional mechanisms. We found that p-
DNp63a bound to target gene promoters, and regulated the activity of the tested promoters
in vitro. P-DNp63a was shown to upregulate miR-185-5p and downregulate let7-5p, which subse-
quently modulated AQP3, CASP14, ALOX12B and CLDN1 through their respective 30-untranslated
regions. The introduction of miR-185-5p into resistant SCC-11M cells, which are unable to phosphor-
ylate DNp63a, render these cells more sensitive to cisplatin treatment. Further studies of the AQP3,
CASP14, ALOX12B, and CLDN1 contributions to chemoresistance may assist in developing novel
microRNA-based therapies for human SCC.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
TP63 gene encoding proteins with the transactivation domain
(TA) and without it (DN) is rarely mutated in cancer, however
is often mutated in ectodermal dysplasia [1–4]. Tp63 null mice
display the single-layered and translucent skin, which is unable
to prevent water loss [5,6]. Homozygous DNp63 null mice show
under-developed stratiﬁed epidermis with clusters of disorganized
epithelial cells exhibiting a premature expression of terminal dif-
ferentiation markers [7]. Many TP63 (tp63) downstream targets
were shown to be involved in skin epithelial sheet architecture,
including aquaporin-3 (AQP3), claudin-1 (CLDN1) [8,9]. AQP3 is
the most abundantly present in the plasma membrane of epider-
mal keratinocytes [10]. Cldn1 null mice have shown alterations of
skin epidermal barrier similar, but not the same to those observed
in tp63 null mice suggesting the probable link between tp63 and
Cldn1 expression [11,12]. Knockdown of tp63 and silencing of
DNp63 reduced Cldn1 expression in mice, while DNp63a binds
to the Cldn1 promoter, and activates the Cldn1 promoter in vitro
[12]. TP63 mutations associated with the ectodermal dysplasia
show the inhibitory effect on CLDN1 expression in the human
epidermal keratinocytes [12].
Caspase-14 (CASP14) is associated with the cellular senescence
leading to a terminal differentiation of epidermal keratinocytes andepidermal barrier formation that protects against dehydration [13].
Casp14 is expressed only in the differentiating layers of the mouse
epidermis and the hair follicle, but not in proliferating keratinocytes
[14,15]. The ultraviolet (UV)-B irradiation is known to cause skin
carcinomas resembling human squamous cell carcinomas (SCC) in
hairlessmice [16]. However, the Casp14mRNA levels were decreased
in UV-induced SCC in mice, while the CASP14 expression was in-
creased in highly differentiated areas of human lung SCC and cervix
carcinoma [15,17]. Arachidonate 12R-lipoxygenase (Alox12b) shown
to be involved in mouse epidermal differentiation and skin barrier
formation is induced in epidermoid carcinomas contributing to the
tumor cell proliferation [18]. Genetic inactivation of Alox12b leads
to thickening of the epidermis, hyper-proliferation of epidermal cells,
and severe hyperkeratosis inmice [19], while the ALOX12B inhibition
enhances human tumor cell death [20].
Cisplatin was reported to induce an ATM kinase-dependent
phosphorylation of DNp63a (p-DNp63a) in SCC cells [21]. Result-
ing p-DNp63a was shown to modulate the expression of mRNA
and microRNAs through a preferential binding to the speciﬁc pro-
moters in SCC cells [22–24]. We found that the microRNAs upreg-
ulated by p-DNp63a subsequently repress the proteins involved in
cell cycle arrest, apoptosis and autophagy [24,25]. In this report,
p-DNp63a was shown to affect the expression of several key pro-
teins involved in epithelial differentiation (AQP3, CASP14, ALOX12B,
and CLDN1) in SCC cells upon cisplatin treatment through a direct
transcriptional regulation, and indirectly via speciﬁc microRNAs,
whose transcription was affected by p-DNp63a [22–25].
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2.1. Cells, reagents and antibodies
We used SCC-11 cells derived from the primary larynx SCC, and
engineered SCC-11M cells with the altered ATM phosphorylation
of DNp63a at the S385G position [21,25]. We also used SCC-25
cells and SCC-25CP cells (with a spontaneously acquired cisplatin
resistance) derived from the primary tongue SCC and obtained
from Dr. J.S. Lazo [reviewed in 25]. Cells were incubated with con-
trol medium or 10 lg/ml cis-diammine-dichloro-platinum-dichlo-
ride (cisplatin, Sigma, P4394). Total lysates were analyzed by
immunoblotting [25] with the antibodies against b-actin (Sigma),
CASP14 (PAB0250), and CLDN1 (H00009076-M01), both from
Abnova, AQP3 (ab15117, Abcam), and ALOX12B (PA5-23608, Ther-
mo Scientiﬁc-Pierce). Immunoblots were scanned using a Phos-
phorImager SI and quantiﬁed by the Image Quant software
version 3.3 (both from Molecular Dynamics).
2.2. Quantitative (q)-PCR
A qPCR was performed using the following kits: AQP3
(Hs01105469_g1), CASP14 (Hs00201637_m1), ALOX12B (Hs00153
961_m1), and CLDN1 (Hs00221623_m1), all from Ambion. Reaction
conditions were 50 C for 2 min, 95 C for 10 min, 40 cycles of 95 C
for 15 s and 60 C for 1 min in 20 ll [25].
2.3. Chromatin immunoprecipitation (ChIP)
5  106 Cell equivalents of chromatin (2–2.5 kb in size) were
precipitated with the 10 lg of anti-DNp63 antibody (PC373, EMD
Chemicals), and normal rabbit immunoglobulin (IgG) used as a
negative control [22]. Enriched DNA was ampliﬁed during 40
cycles at 94 C for 30 s, 60 C for 30 s and 72 C for 30 s. The enrich-
ment binding of endogenous p-DNp63a to the speciﬁc promoter
regions were assessed by qPCR assays. ChIP-qPCR values (relative
units, RU) were normalized by the glycerladehyde-3-phospho-
dehydrogenase (GAPDH) values and presented as fold changes of
ChIP-qPCR over Input qPCR divided by 100. Experiments were
performed in triplicate.
2.4. Transfection with microRNA mimics and inhibitors
Mimics (hsa-miR-185-5p, MC12486; hsa-let7-5p, MC10050) or
inhibitors (hsa-miR-185-5p, AM12486; hsa-let7-5p, MH10050)
were obtained from Ambion. Cells in 6-well plate were transfected
with 100 pmol of microRNA reagents in 500 ll serum-free media
containing 5 ll of Lipofectamine-2000 reagent (Invitrogen) for
36 h. Each experiment was performed independently 3 times and
in triplicate [24].
2.5. Luciferase reporter assay
The promoter–reporter plasmids for AQP3 (S713245), CASP14
(S720887), CLDN1 (S705045), and ALOX12B (S713034), as well as
the 30-UTR luciferase reporter plasmids for AQP3 (S806648), CLDN1
(S811664), were obtained from SwitchGear Genomics. CASP14 30-
UTR Lentivirus (MV-h03514, Applied Biological Material Inc.) and
pEZX-MT01-ALOX12B-30-UTR plasmid (HmiT006376-MT01, Gene-
Copoeia) were handled according to the manufacturers’ protocols.
For the luciferase activity assays, cells in 24-well plate were trans-
fected with the pLightSwitch_Prom vectors or pLightSwitch_3UTR
vectors for 24 h using Fugene HD reagent (Roche). Cells were also
transfected with 100 ng of microRNA mimics/inhibitors for 36 h.
Luciferase reporter activity was monitored using the LightSwitch
Luciferase Assay Reagent at 480 nm [24].2.6. Cell viability assay
Cells in 96-well plate were incubated in serum-free medium
with 5 lg/ml of the 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tet-
razolium bromide (MTT, American Tissue Culture Collection) in the
dark at 37 C for 4 h. Lysed cells were incubated at 37 C for 2 h and
the A570nm/A650nm measurements were obtained on a Spectra Max
250 plate reader (Molecular Devices). Each assay was repeated
three times in triplicate [24].
2.7. Statistical analysis and bioinformatics
Data represent mean ± S.D., and the statistical differences in
variables between experimental and control groups assessed by
using the Student t test were accepted at a signiﬁcance level of P
<0.05 to <0.001. The microRNA ‘seed’ sequences in target 30-UTRs
were predicted using the miRDB-MicroRNA Target Prediction and
Functional Study Database, v3.0 (www.mirdb.org).
3. Results
3.1. P-DNp63a affects the expression of AQP3, CASP14, ALOX12B, and
CLDN1 in SCC cells
P-DNp63a was shown to directly regulate transcription of the
speciﬁc mRNA and microRNA encoding genes [21,23,24]. The
putative TP63-binding sites were found in the promoter se-
quences of a few genes implicated in epithelial differentiation,
such as AQP3, ALOX12B, CASP14, and CLDN1 (Figs. S1–S4). We used
larynx SCC-11 cells expressing wild type DNp63a and SCC-11M
cells expressing DNp63a-S385G with the altered ability to be
phosphorylated by ATM kinase [21]. We also used the tongue
SCC-25 and SCC-25CP cells [25]. Both SCC-11M and SCC-25CP dis-
played the more resistant to cisplatin phenotype then SCC-11 and
SCC-25, respectively [25]. We showed that the expression of
AQP3, CASP14, ALOX12B, and CLDN1 transcripts was induced in
sensitive SCC-11 cells and SCC-25 cells compared to resistant
SCC-11M cells and SCC-25CP cells upon cisplatin exposure
(Fig. 1A). We further showed that DNp63a bound to the speciﬁc
regions (SR) of the AQP3, CASP14, ALOX12B, and CLDN1 promoters
in SCC-11 cells (or SCC-25 cells) in greater degree than in SCC-
11M cells (or SCC-25CP cells) supporting the role for p-DNp63a
in the this process (Fig. 1B). However, DNp63a showed no signif-
icant binding to the non-speciﬁc regions (NSR) of the AQP3,
CASP14, ALOX12B, and CLDN1 promoters, and a normal rabbit
IgG failed to signiﬁcantly bind to the SR of the tested promoters
in SCC-11/SCC-11M pair (Fig. S5) or SCC-25/SCC-25CP pair
(Fig. S6). We next showed that p-DNp63a (SCC-11 cells or SCC-
25 cells) induced expression of the luciferase reporter gene linked
to the AQP3, CASP14, ALOX12B, and CLDN1 promoters compared to
that of non-p-DNp63a (SCC-11M cells and SCC-25CP cells), as
seen in Fig. 1C.
3.2. P-DNp63adependent microRNA modulate AQP3, CASP14,
ALOX12B, and CLDN1
We previously found that p-DNp63a could indirectly regulate
the expression of proteins via speciﬁc microRNAs, whose transcrip-
tion pattern was affected by p-DNp63a [22,24,25]. Among them
were miR-185-5p, and let7-5p [25]. Although miR-185-5p was
induced in SCC-11 cells, let7-5p was reduced in SCC-11 cells upon
cisplatin exposure compared to SCC-11M cells treated with
cisplatin [25]. We predicted that miR-185-5p is likely to target
the AQP3, CASP14, and ALOX12B 30-UTR, while let7-5p might target
the CLDN1 30-UTR (target prediction scores 63–89). To validate
these predictions, we examined whether these microRNAs could
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Fig. 1. Cisplatin induced the transcription of the CLDN1, ALOX12B, AQP3 and CASP14 genes in SCC cells. Both SCC-11/SCC-11M pair and SCC-25/SCC-25CP pair were exposed to
10 lg/ml cisplatin for 16 h. (A). QPCR assay of CLDN1, ALOX12B, AQP3 and CASP14 genes. QPCR values presented as fold change of relative units (RU) normalized to the GAPDH
PCR values (as a host gene) and to the values obtained for SCC-11M cells (or SCC-25CP) designated as 1. (⁄) Indicates signiﬁcant difference (P < 0.05). (B). QPCR analysis of the
DNp63a-enriched binding to the speciﬁc regions of the indicated gene promoters (CLDN1, ALOX12B, AQP3 and CASP14) in vitro. The amount of ChIP-enriched DNA in each
sample presented as signal relative units (RU) to the total amount of input chromatin DNA (input) using the same primers, then normalized to the GAPDH PCR values.
Resulting ChIP/Input ratios were divided by 100 (⁄, P < 0.05, n = 3, compared to control data presented in Figs. S5 and S6). (C). Activation of the CLDN1, ALOX12B, AQP3 and
CASP14 promoters by p-DNp63a in vitro. Both SCC-11/SCC-11M pair and SCC-25/SCC-25CP pair were transfected with 100 ng of the LightSwitch_Pro reporter plasmids
containing the indicated promoters for 36 h. Cells were exposed to 10 lg/ml cisplatin (CIS) for an additional 12 h. Values from SCC-11 cells (or SCC-25 cells) presented as fold-
change relative luciferase units (RLU) normalized to data obtained from the SCC-11M cells (or SCC-25CP cells) designated as 1. Experiments were performed in triplicate and
statistical differences were accessed by Student t-test (⁄P < 0.05, n = 3).
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sequences of target mRNA in SCC-11 cells. SCC-11 cells were trans-
fected with the scrambled RNA (ScrRNA) or indicated microRNA
mimics/inhibitors along with the LightSwitch UTR plasmids for
AQP3, CASP14, and ALOX12B, and CLDN1 for 36 h (Fig. 2A and B).
Resulting SCC-11 cells were exposed to control medium (Con)
and 10 lg/ml cisplatin (CIS) for 12 h. Cisplatin treatment reduced
the luciferase reporter activities driven by both AQP3 and CASP14
30-UTR (Fig. 2A), while and reduced the activity driven by
ALOX12B-3’-UTR, while induced the activity driven by CLDN1 3’-
UTR (Fig. 2B). The miR-185-5p mimic reduced the AQP3, CASP14,
and ALOX12B 30-UTR driven activities, while miR-185-5p inhibitors
activated these activities in vitro (Fig. 2A and B). Similarly, bothlet7-5p mimic reduced the luciferase activity under control of
CLDN1 30-UTR, while inhibitors for let7-5p induced this activity
in vitro (Fig. 2B). Tested microRNA mimic and inhibitors also
modulated the AQP3, CASP14, CLDN1 and ALOX12B protein levels
in SCC-11 cells (Fig. 2C and D). Similar effects for miR-185-5p and
Let7-5p on the AQP3, CASP14, ALOX12B 3’-UTR, and CLDN1 3’-UTR
were shown in the SCC-25 cells (Fig. 2E and F).
We further showed that the AQP3, CASP14, and ALOX12B pro-
tein levels were downregulated, while the CLDN1 level was upreg-
ulated by cisplatin in SCC-11 cells and SCC-25 cells compared to
control conditions without cisplatin (Fig. 3A and B, upper panels).
However, the AQP3, CASP14, CLDN1 and ALOX12B protein levels
were slightly changed in SCC-11M cells and SCC-25CP cells by
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Fig. 2. MicroRNAs modulated the expression of the protein targets in SCC cells. Cells were transfected with scrambled (Scr) RNA for 36 h before exposing them to control
medium (Con) or 10 lg/ml cisplatin (CIS) for 12 h. Experiments were run in triplicates and (⁄) indicate signiﬁcant difference (P < 0.05). MicroRNA/30-UTR luciferase reporter
assays for indicated targets in SCC-11 cells (A and B) and SCC-25 cells (E and F) exposed to control medium. Target protein symbols are indicated above the graph, while
speciﬁc microRNA mimics/inhibitors – below the graph. (C and D) Mimics and inhibitors for miR-185-5p and Let7-5p affected the AQP3, CASP14, CLDN1 and ALOX12B levels
in SCC-11 cells.
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and B, lower panels).
Finally, we examined the effect of miR-185-5 mimic on resis-
tant SCC-11M cells (Fig. 3C) and SCC-25CP cells (Fig. 3D). SCC-11/
SCC-11M pair (Fig. 3C), as well as SCC-25/SCC-25CP pair (Fig. 3D)
of cells were transfected with the scrambled RNA (ScrRNA). SCC-
11M cells and SCC-25CP cells were also transfected with miR-
185-5p mimic for 32 h. Cells were grown-up without (Con, curve
1) or with 10 lg/ml cisplatin (CIS, curves 2–4) for 16 h (Fig. 3C
and D). We observed that the cisplatin exposure reduced the via-
bility of SCC-11M cells (Fig. 3C, curve 2 compared to curve 1), while
its effect on SCC-11 cells appeared to be greater (Fig. 3C, curve 4
compared to curve 2). Intriguingly, the introduction of the miR-
185-5p mimic into SCC-11M cells rendered them more sensitive
to cisplatin (Fig. 3C, curve 3 compared to curve 2). Similar effects
were shown for SCC-25CP cells (Fig. 3D).
4. Discussion
In this study, we used the larynx-derived SCC-11 and SCC-11M
(with the S385G mutation in DNp63a and more resistance tocisplatin), and the tongue-derived SCC-25 and SCC-25CP (with a
spontaneously acquired resistance to cisplatin). While SCC-11M
cells failed to support the phosphorylation of DNp63a by ATM
kinase upon cisplatin exposure due to S385G mutation, the
SCC-25CP cells were shown to express a lesser p-DNp63a/non-p-
DNp63a ratio than SCC-25 cells further supporting a potential
p-DNp63a contribution to a cisplatin sensitivity of SCC cells [26].
Overall, we showed that the cisplatin treatment of SCC-11 cells
led to a exclusive production of p-DNp63a resulting in induction
of the AQP3, CASP14, and ALOX12B, and CLDN1 expression. We
found that p-DNp63a bound to the AQP3, CASP14, ALOX12B, and
CLDN1 promoters, as well as activated the luciferase reporter
activity driven by these promoters in vitro. We further found that
miR-185-5p and Let7-5p, whose transcription is regulated by p-
DNp63a in SCC cells exposed to cisplatin, modulated the luciferase
activities driven by the AQP3, CASP14, ALOX12B, and CLDN1 30-UTR
sequences in vitro. We also showed that cisplatin exposure, which
induced the p-DNp63a- dependent miR-185-5p expression, led to
a decrease of the AQP3, CASP14 and ALOX12B protein levels in
SCC-11 cells, while no signiﬁcant changes were shown in SCC-
11M cells. Finally, the introduction of the miR-185-5p mimic into
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able sensitization of these cells to the cisplatin-induced cell death
shown by a decrease in their cell viability.
These p-DNp63a-dependent targets were previously reported
to play a critical role in epithelial differentiation, tight junction,
skin barrier permeability potentially contributing to tumor devel-
opment and chemoresistance [8,9]. Alterations in Alox12b expres-
sion were shown to be often associated with the defective skin
barrier functions subsequently resulting in epidermal hyper-prolif-
eration [19,27]. CLDN1 was shown to act as a signal mediator to
regulate gene expression and cell migration in human oral and
lung cancer cells [11,28].
Emerging data show that AQP3 and CASP14 are important deter-
minants in epidermal proliferation and skin tumorigenesis [29–
33]. The Aqp3 null mice showed resistance to a development of
skin tumorigenesis, since epidermal hyperplasia was reduced in
Aqp3/ mice, which show a decreased proliferation of mouse
keratinocytes [29]. At the same time, the AQP3 mRNA and AQP3
protein levels were signiﬁcantly increased in the epidermis ofhuman atopic dermatitis lesions supporting the involvement of
AQP3 in epidermal hyperplasia in skin diseases and placing AQP3
as a potential target for drug development against skin cancer
[30,31]. The AQP3 upregulation was observed in human primary
SCC of esophageal and lingual origin compared to normal tissue
counterparts [31,32]. The pan-AQP inhibitor caused apoptosis in
the SCC cells, while AQP3 siRNA inhibited cell adhesion and growth
of SCC cells, especially in combination with cisplatin [32].
The link between CASP14 and keratinocyte senescence supports
the notion that this developmentally regulated protease might
contribute to tumorigenesis [15]. Alterations in CASP14 expression
were associated with cell differentiation, tumor cell growth, and
metastatic potential in breast, cervical, ovarian, and colorectal
cancers [14,15,17]. CASP14 was reported to interact with apopto-
sis-inducing factor, while CASP14 silencing reduced cisplatin
resistance in lung carcinoma cells [33]. Withdrawal from the cell
cycle and commitment to terminal differentiation, which is linked
to CASP14 expression [15], might also contribute to attenuated cell
viability of SCC-11 cells upon cisplatin-/p-DNp63a-dependent cell
3586 E.A. Ratovitski / FEBS Letters 587 (2013) 3581–3586cycle arrest. Further studies of these pathways may assist in
developing of novel anti-cancer therapeutic targets, especially
when the speciﬁc microRNA-based therapies could be applied to
the personalized tumorgrafts of epithelial human cancers.
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